Immunocore soars 17% as FDA approves Kimmtrak for uveal melanoma

Immunocore's (NASDAQ:IMCR) medicine Kimmtrak (tebentafusp-tebn) was approved by the U.S. Food and Drug Administration (FDA) to treat HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), a type of cancer affecting the eye.